TY  - JOUR
AU  - García-Pérez, Javier
AU  - Staropoli, Isabelle
AU  - Azoulay, Stéphane
AU  - Heinrich, Jean-Thomas
AU  - Cascajero Díaz, Almudena
AU  - Colin, Philippe
AU  - Lortat-Jacob, Hugues
AU  - Arenzana-Seisdedos, Fernando
AU  - Alcamí, José
AU  - Kellenberger, Esther
AU  - Lagane, Bernard
PY  - 2015
DO  - 10.1186/s12977-015-0177-1
SN  - 1742-4690
UR  - http://hdl.handle.net/20.500.12105/10238
AB  - BACKGROUND: Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. While MVC-resistant viruses have been identified in patients, it still remains incompletely known how they adjust their CD4 and CCR5 binding properties to resist...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Anti-HIV Agents
KW  - Cyclohexanes
KW  - HIV Envelope Protein gp120
KW  - HIV-1
KW  - Humans
KW  - Maraviroc
KW  - Mutant Proteins
KW  - Protein Binding
KW  - Receptors, CCR5
KW  - Receptors, HIV
KW  - Triazoles
KW  - Virus Internalization
KW  - Virus Replication
KW  - Drug Resistance, Viral
KW  - Mutation, Missense
TI  - A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
TY  - journal article
ER  -